Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas
Gut and Liver · 15.03.2023 · 17 (2) · 288-298
DOI: 10.5009/gnl210551 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gut and Liver, online erschienen am 21.10.2022. Verfasst von Ting-Yuan Lan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B, Autoimmune Diseases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Douliu, Taiwan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
- Division of Rheumatology, Department of Internal Medicine, National Taiwan University, Taipei, Taiwan.
ORCID-Profile: Ting-Yuan Lan, Yen-Chun Lin, Tai-Chung Tseng, Hung-Chih Yang, Jui-Hung Kao, Chiao-Feng Cheng, Tai-Ju Lee, Shang-Chin Huang, Cheng-Hsun Lu, Ko-Jen Li, Song-Chou Hsieh
Zitieren
APA
Lan, T. Y., Lin, Y. C., Tseng, T. C., Yang, H. C., Kao, J. H., Cheng, C. F., Lee, T. J., Huang, S. C., Lu, C. H., Li, K. J., & Hsieh, S. C. (2023). Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas. Gut and Liver, 17(2), 288-298. https://doi.org/10.5009/gnl210551
Vancouver
Lan TY, Lin YC, Tseng TC, Yang HC, Kao JH, Cheng CF, et al. Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas. Gut and Liver. 2023;17(2):288-298. doi:10.5009/gnl210551
BibTeX
@article{Lan2023,
author = {Lan, Ting-Yuan and Lin, Yen-Chun and Tseng, Tai-Chung and Yang, Hung-Chih and Kao, Jui-Hung and Cheng, Chiao-Feng and Lee, Tai-Ju and Huang, Shang-Chin and Lu, Cheng-Hsun and Li, Ko-Jen and Hsieh, Song-Chou},
title = {Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas},
journal = {Gut and Liver},
year = {2023},
volume = {17},
number = {2},
pages = {288--298},
doi = {10.5009/gnl210551}
}
EUVIMED